Status:

COMPLETED

Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair

Lead Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Acute Kidney Injury

Abdominal Aortic Aneurysm

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this program of research is to determine whether curcumin, a natural health product, can prevent acute kidney injury and other complications after elective AAA repair. If proven safe an...

Detailed Description

An abdominal aortic aneurysm (AAA) is a ballooning of the abdominal aorta, the major blood vessel of the body. AAA occurs in up to 2% of adults. Surgeons will plan an AAA repair when the aneurysm grow...

Eligibility Criteria

Inclusion

  • Elective repair of an AAA (excludes thoracic or thoracoabdominal aneurysms)
  • 18 years of age or older
  • Able to provide informed consent
  • Has one or more of the following criteria at time of preoperative assessment:
  • x Open repair OR
  • x Endovascular repair with ≥ 1 of the following criteria:
  • o diabetes mellitus treated with insulin or oral hypoglycemic agents
  • o age \> 70 years
  • o pre-existing renal impairment (baseline serum creatinine level \>177 μmol/L for men or \>146 μmol/L for women)
  • If diabetic, is able and willing to collect and record glucose levels at home

Exclusion

  • emergent or urgent repair (repair \< 3 days from pre-admission visit; ruptured AAA)
  • prior renal transplantation
  • pregnant or breastfeeding
  • active gastrointestinal reflux disease, gastrointestinal ulcers or hepatobiliary disease (including gallstones)
  • has active liver disease
  • evidence of AKI (\> 50% increase in serum creatinine) in the 30 days prior to repair
  • enrolled in another randomized controlled trial
  • receipt of ≥ 1 dialysis treatment in the past week
  • previous participation in this trial
  • repair is scheduled \> 90 days from date of informed consent
  • unable to provide written consent
  • allergy(ies) to any member of the Zingiberaceae family: turmeric, ginger, curry, cumin, cardamom)
  • allergy(ies) to ingredients of the study product or placebo: yellow or red food coloring, gelatin or cellulose
  • have a history of major bleeding event in the previous 6 months
  • bleeding disorders: a diagnosis of hemophilia, von Willebrand disease, platelets less than 70 for any reason
  • history of hypoglycemia in the past 6 months: blood sugar less than or equal to 3.5 mmol/L

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2016

Estimated Enrollment :

606 Patients enrolled

Trial Details

Trial ID

NCT01225094

Start Date

November 1 2011

End Date

August 1 2016

Last Update

March 7 2017

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

University of Calgary

Calgary, Alberta, Canada, T3B 6A8

2

University of Alberta Hospital

Edmonton, Alberta, Canada, T6G 2B7

3

St. Boniface Hospital

Winnipeg, Manitoba, Canada, R2H 2A6

4

Sudbury Regional Hospital

Greater Sudbury, Ontario, Canada, P3E5J1